Products - Renal cancer | Topic | NICE

Showing 7 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Renal cell carcinoma Pathways Pilot [ID6186]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Kidney Cancer
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Kidney Cancer
Status:
In development
Expected publication date:
TBC